Patients With Opioid Addiction Benefit From Tx Initiated in ER

Share this content:
Patients With Opioid Addiction Benefit From Tx Initiated in ER
Patients With Opioid Addiction Benefit From Tx Initiated in ER

TUESDAY, Feb. 21, 2017 (HealthDay News) -- Patients addicted to opioids treated in a hospital emergency department do better when they receive medication to reduce opioid cravings, according to a study published online Feb. 13 in the Journal of General Internal Medicine.

The study looked at 290 patients addicted to opioids who went to an emergency department. They received one of three treatments: a referral to addiction treatment services; a short interview, including discussion of treatment; or a brief interview and the medication buprenorphine. The patients given medication also continued treatment with their primary care doctor.

After two months of follow-up, the researchers found that patients who received buprenorphine were more likely to be in formal addiction treatment and to report reduced opioid use than those in the other two groups.

"The emergency department visit is an ideal opportunity to identify patients with opioid use disorder and initiate treatment and direct referral, similar to best practices for other diseases, such as high blood pressure and diabetes," study co-leader Gail D'Onofrio, M.D., chair of emergency medicine at the Yale School of Medicine in New Haven, Conn., said in a Yale news release.

The study was supported by the National Institute on Drug Abuse (NIDA). Reckitt Benckiser Pharmaceuticals provided buprenorphine through the NIDA.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »